Genomic Assays in Node Positive Breast Cancer Patients: A Review
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media S.A.
Abstract
In recent years, developments in breast cancer have allowed yet another realization of individualized medicine in the field of oncology. One of these advances is genomic assays, which are considered elements of standard clinical practice in the management of breast cancer. These assays are widely used today not only to measure recurrence risk in breast cancer patients at an early stage but also to tailor treatment as well and minimize avoidable treatment side effects. At present, genomic tests are applied extensively in node negative disease. In this article, we review the use of these tests in node positive disease, explore their ramifications on neoadjuvant chemotherapy decisions, highlight sufficiently powered recent studies emphasizing their use and review the most recent guidelines. © Copyright © 2021 Bou Zerdan, Ibrahim, Nakib, Hajjar and Assi.
Description
Keywords
Breast cancer, Breast cancer index, Endopredict, Genomic grade index, Immunohistochemistry, Mammaprint, Oncotype dx, Pam50, Anastrozole, Anthracycline, Bag 1 protein, Beta actin, Beta glucuronidase, Cathepsin v, Cd68 antigen, Cd71 antigen, Cyclin b1, Cyclophosphamide, Doxorubicin, Epidermal growth factor receptor 2, Estrogen receptor, Exemestane, Fluorouracil, Glutathione transferase m1, Growth factor receptor bound protein 2, Ki 67 antigen, Paclitaxel, Pertuzumab, Progesterone receptor, Protein myb, Survivin, Tamoxifen, Trastuzumab, Cancer patient, Cancer prognosis, Cancer recurrence, Cancer staging, Disease free survival, Dna microarray, Fluorescence in situ hybridization, Follow up, Gene expression, Genetic analysis, Histology, Human, Lymphoid tissue, Mrna expression level, Neoadjuvant chemotherapy, Oncological parameters, Overall survival, Recurrence free survival, Recurrence risk, Reverse transcription polymerase chain reaction, Review, Tumor volume